EVOFEM BIOSCIENCES INC (EVFM) Forecast, Price Target & Analyst Ratings
NASDAQ:EVFM • US30048L2034
0.4782 USD
-0.15 (-23.37%)
At close: Aug 10, 2022
0.4405 USD
-0.04 (-7.88%)
After Hours: 8/10/2022, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for EVOFEM BIOSCIENCES INC (EVFM).
Forecast Snapshot
Consensus Price Target
$11.27
+ 2,256.96% Upside
Next Earnings Forecast
Release DateNov 14, 2022
ChartMill Buy Consensus
80.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$11.27
Upside
+ 2,256.96%
From current price of $0.48 to mean target of $11.27, Based on 11 analyst forecasts
Low
$0.76
Median
$3.57
High
$47.25
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
11 analysts have analysed EVFM and the average price target is 11.27 USD. This implies a price increase of 2256.96% is expected in the next year compared to the current price of 0.4782.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
EVFM was analyzed by 11 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about EVFM.
In the previous month the buy percentage consensus was at a similar level.
EVFM was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-12-13 | Laidlaw & Co. | Downgrade | Buy -> Hold |
| 2022-10-13 | Stifel | Downgrade | Buy -> Hold |
| 2022-08-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-07-15 | Morgan Stanley | Maintains | Underweight |
| 2022-06-02 | Laidlaw & Co. | Initiate | Buy |
| 2022-05-25 | Piper Sandler | Maintains | Overweight |
| 2022-05-11 | Morgan Stanley | Maintains | Underweight |
| 2022-05-10 | Morgan Stanley | Maintains | Underweight |
| 2022-04-12 | Morgan Stanley | Maintains | Underweight |
| 2022-03-04 | Morgan Stanley | Maintains | Underweight |
| 2021-11-16 | HC Wainwright & Co. | Maintains | Buy |
| 2021-10-21 | HC Wainwright & Co. | Maintains | Buy |
| 2021-10-14 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2021-08-12 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-06-07 | HC Wainwright & Co. | Maintains | Buy |
| 2021-03-08 | HC Wainwright & Co. | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateNov 14, 2022
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 450K | 8.244M 1,732.00% | 32.556M 294.91% | 61.392M 88.57% | 101.25M 64.92% | 175.449M 73.28% | 310.104M 76.75% | ||
| EBITDA YoY % growth | -52.48M 32.18% | -103.32M -96.88% | -165.778M -60.45% | -101.133M 38.99% | -61.45M 39.24% | -41.382M 32.66% | -55.155M -33.28% | -74.982M -35.95% | |
| EBIT YoY % growth | -52.74M 32.07% | -103.62M -96.47% | -166.801M -60.97% | -92.929M 44.29% | -71.467M 23.10% | -41.448M 42.00% | -53.862M -29.95% | -71.394M -32.55% | |
| Operating Margin | N/A | -23,026.67% | -2,023.30% | -285.44% | -116.41% | -40.94% | -30.70% | -23.02% | |
| EPS YoY % growth | -1.49 53.29% | -2.18 -46.31% | -12.98 -495.41% | -5.47 57.85% | -1.19 78.31% | -0.59 50.14% | -0.95 -61.01% | -1.56 -64.23% |
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.03%
EPS Next 5 Year
13.45%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
130.74%
Revenue Next 5 Year
106.58%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
EVOFEM BIOSCIENCES INC / EVFM Forecast FAQ
What do analysts expect the price target to be for EVOFEM BIOSCIENCES INC (EVFM)?
11 analysts have analysed EVFM and the average price target is 11.27 USD. This implies a price increase of 2256.96% is expected in the next year compared to the current price of 0.4782.
What is the next earnings date for EVFM stock?
EVOFEM BIOSCIENCES INC (EVFM) will report earnings on 2022-11-14.
How many analysts have analysed EVOFEM BIOSCIENCES INC (EVFM)?
The number of analysts covering EVOFEM BIOSCIENCES INC (EVFM) is 11.